Intech Investment Management LLC Buys 6,141 Shares of Immunome, Inc. $IMNM

Intech Investment Management LLC increased its stake in Immunome, Inc. (NASDAQ:IMNM) by 17.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,565 shares of the company’s stock after purchasing an additional 6,141 shares during the period. Intech Investment Management LLC’s holdings in Immunome were worth $377,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of IMNM. Creative Planning acquired a new stake in Immunome during the second quarter worth about $167,000. Candriam S.C.A. acquired a new position in shares of Immunome in the 2nd quarter valued at approximately $2,958,000. Geode Capital Management LLC lifted its holdings in shares of Immunome by 6.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock worth $17,305,000 after acquiring an additional 117,523 shares during the period. Nan Fung Trinity HK Ltd. acquired a new stake in shares of Immunome during the 2nd quarter worth approximately $5,104,000. Finally, Los Angeles Capital Management LLC increased its stake in Immunome by 16.8% in the second quarter. Los Angeles Capital Management LLC now owns 41,857 shares of the company’s stock valued at $389,000 after acquiring an additional 6,009 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

IMNM has been the subject of several recent analyst reports. Craig Hallum started coverage on Immunome in a research note on Friday, September 5th. They set a “buy” rating and a $26.00 target price for the company. Guggenheim reaffirmed a “buy” rating and set a $25.00 price target on shares of Immunome in a report on Monday, August 25th. The Goldman Sachs Group assumed coverage on Immunome in a report on Monday, September 22nd. They issued a “buy” rating and a $26.00 target price for the company. Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, JPMorgan Chase & Co. lowered their price objective on Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $23.78.

Immunome Price Performance

Shares of Immunome stock opened at $18.23 on Monday. Immunome, Inc. has a one year low of $5.15 and a one year high of $19.16. The business has a 50-day simple moving average of $15.32 and a 200 day simple moving average of $11.52. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -6.18 and a beta of 1.96.

Immunome (NASDAQ:IMNM) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, sell-side analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.